TY - JOUR
T1 - 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe
T2 - Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children
AU - I-MOVE/I-MOVE+ study team
AU - Kissling, Esther
AU - Valenciano, Marta
AU - Pozo, Francisco
AU - Vilcu, Ana Maria
AU - Reuss, Annicka
AU - Rizzo, Caterina
AU - Larrauri, Amparo
AU - Horváth, Judit Krisztina
AU - Brytting, Mia
AU - Domegan, Lisa
AU - Korczyńska, Monika
AU - Meijer, Adam
AU - Machado, Ausenda
AU - Ivanciuc, Alina
AU - Višekruna Vučina, Vesna
AU - van der Werf, Sylvie
AU - Schweiger, Brunhilde
AU - Bella, Antonino
AU - Gherasim, Alin
AU - Ferenczi, Annamária
AU - Zakikhany, Katherina
AU - O′Donnell, Joan
AU - Paradowska-Stankiewicz, Iwona
AU - Dijkstra, Frederika
AU - Guiomar, Raquel
AU - Lazar, Mihaela
AU - Kurečić Filipović, Sanja
AU - Johansen, Kari
AU - Moren, Alain
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Background: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. Methods: We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. Results: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: −32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: −38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: −4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was −47.6% (95% CI: −124.9 to 3.1), 27.3% (95% CI: −4.6 to 49.4) and 9.3% (95% CI: −44.1 to 42.9), respectively. Conclusions: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine.
AB - Background: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. Methods: We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. Results: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: −32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: −38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: −4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was −47.6% (95% CI: −124.9 to 3.1), 27.3% (95% CI: −4.6 to 49.4) and 9.3% (95% CI: −44.1 to 42.9), respectively. Conclusions: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine.
KW - case-control study
KW - influenza
KW - influenza vaccine
KW - multicentre study
KW - vaccine effectiveness
UR - http://www.scopus.com/inward/record.url?scp=85043684377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043684377&partnerID=8YFLogxK
U2 - 10.1111/irv.12520
DO - 10.1111/irv.12520
M3 - Article
C2 - 29125681
AN - SCOPUS:85043684377
VL - 12
SP - 423
EP - 437
JO - Influenza and other Respiratory Viruses
JF - Influenza and other Respiratory Viruses
SN - 1750-2640
IS - 4
ER -